EX-10.210-Q·CIK 1374690·0001193125-26-462242

First Amendment to Employment Agreement

View original filing on SEC EDGAR → ·  seen Nov 16, 2026, 08:33 EST

FIRST AMENDMENT TO EMPLOYMENT AGREEMENT

This First Amendment to Employment Agreement (this “Amendment”) is made effective as of November 11, 2026 (the “Amendment Effective Date”), by and between LARIMAR THERAPEUTICS, INC. (the “Company”) and JOHN B. HARLOW, JR. (the “Executive”). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to them in the Employment Agreement (as defined below).

WHEREAS, the Company and the Executive are parties to an Employment Agreement dated September 3, 2026 (the “Employment Agreement”); and

WHEREAS, the Company and the Executive wish to amend certain provisions of the Employment Agreement.

NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

1.

Section 5 of the Employment Agreement is hereby amended by adding the following sentences after the first sentence, as follows:

Nothing contained in this Agreement, the Confidentiality, Intellectual Property Assignment and Restrictive Covenant Agreement, or any other agreement with the Company, or any Company policy limits Executive’s ability, with or without notice to the Company, to: (1) file a charge or complaint with any federal, state or local governmental agency or commission (a “Government Agency”), including, without limitation, the Equal Employment Opportunity Commission, the National Labor Relations Board or the Securities and Exchange Commission (the “SEC”), and including, without limitation, in accordance with the provisions of and rules promulgated under Section 21F of the Securities Exchange Act of 1934, as amended, or Section 806 of the Sarbanes-Oxley Act of 2002, or of any other whistleblower protection provisions of federal law or regulation; (2) communicate with any Government Agency or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including by providing non-privileged documents or information; or (3) testify truthfully in a legal proceeding. Any such communications and disclosures must be consistent with applicable law and the information disclosed must not have been obtained through a communication that was subject to the attorney-client privilege (unless disclosure of that information would otherwise be permitted consistent with such privilege or applicable law). Executive further understands that the Company will not limit any right Executive may have to receive an award pursuant to the whistleblower provisions of any applicable law or regulation for providing information to the SEC or any other Government Agency.

2.

All other provisions of the Employment Agreement shall remain in full force and effect according to their respective terms, and nothing contained herein shall be deemed a waiver of any right or abrogation of any obligation otherwise existing under the Employment Agreement except to the extent specifically provided for herein. For the avoidance of doubt, the


Confidentiality, Intellectual Property Assignment and Restrictive Covenant Agreement continues to be in full force and effect.

3.

This Amendment may be executed in any number of counterparts, including counterpart signature pages or counterpart facsimile signature pages, each of which shall be deemed an original, but all of which together shall constitute one and the same document.

[Signature page follows]


IN WITNESS WHEREOF, the parties have executed this Amendment effective on the Amendment Effective Date.

LARIMAR THERAPEUTICS, INC.

By: /s/ Carole Ben-Maimon, M.D.

Name: Carole Ben-Maimon, M.D.

Title: Chief Executive Officer

EXECUTIVE

/s/ John B. Harlow, Jr.

John B. Harlow, Jr.


Back to all agreements